Hi @supertramp
Sorry but I think that the HER-vaxx trial also included local disease just like the Herceptin one. From the HER-vaxx inclusion criteria:
"Metastatic gastric or GEJ adenocarcinoma, or locally advanced disease not amenable to surgical resection"
https://clinicaltrials.gov/ct2/show/NCT02795988
So far there is no data to suggest that HER-vaxx works better than Herceptin. I agree that this is not surprising at this stage given HER-vaxx and Herceptin have the same target ie HER2. We are hoping that the polyclonal antibodies stimulated by HER-vaxx have a more durable effect compared to Herceptin. Time will tell.
Also, I note that the latest Edison research update states:
"The HER2 B-cell vaccines have shown signs of efficacy in clinical studies despite the levels ofpolyclonal anti-HER2 antibodies stimulated by the vaccine being at least an order of magnitudelower than the levels used in anticancer therapy with Herceptin, which also acts on HER2."
https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5b7b7fa50ebbe8b7258f3ac5/1534820272676/Edison+report+final+16aug18.pdf
Hi @supertrampSorry but I think that the HER-vaxx trial also...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2275218 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 196677 | 3 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
